Cargando…

Gini's mean difference and the long-term prognostic value of nodal quanta classes after pre-operative chemotherapy in advanced breast cancer

Gini's mean difference (GMD, mean absolute difference between any two distinct quantities) of the restricted mean survival times (RMSTs, expectation of life at a given time limit) has been proposed as a new metric where higher GMD indicates better prognostic value. GMD is applied to the RMSTs a...

Descripción completa

Detalles Bibliográficos
Autores principales: Vinh-Hung, Vincent, Van Parijs, Hilde, Gorobets, Olena, Fontaine, Christel, Nguyen, Nam P., Keam, Bhumsuk, Nguyen, Dung Minh, De Ridder, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863879/
https://www.ncbi.nlm.nih.gov/pubmed/35194143
http://dx.doi.org/10.1038/s41598-022-07078-7
_version_ 1784655329735213056
author Vinh-Hung, Vincent
Van Parijs, Hilde
Gorobets, Olena
Fontaine, Christel
Nguyen, Nam P.
Keam, Bhumsuk
Nguyen, Dung Minh
De Ridder, Mark
author_facet Vinh-Hung, Vincent
Van Parijs, Hilde
Gorobets, Olena
Fontaine, Christel
Nguyen, Nam P.
Keam, Bhumsuk
Nguyen, Dung Minh
De Ridder, Mark
author_sort Vinh-Hung, Vincent
collection PubMed
description Gini's mean difference (GMD, mean absolute difference between any two distinct quantities) of the restricted mean survival times (RMSTs, expectation of life at a given time limit) has been proposed as a new metric where higher GMD indicates better prognostic value. GMD is applied to the RMSTs at 25 years time-horizon to evaluate the long-term overall survival of women with breast cancer who received neoadjuvant chemotherapy, comparing a classification based on the number (pN) versus a classification based on the ratio (LNRc) of positive nodes found at axillary surgery. A total of 233 patients treated in 1980–2009 with documented number of positive nodes (npos) and number of nodes examined (ntot) were identified. The numbers were categorized into pN0, npos = 0; pN1, npos = [1,3]; pN2, npos = [4,9]; pN3, npos ≥ 10. The ratios npnx = npos/ntot were categorized into Lnr0, npnx = 0; Lnr1, npnx = (0,0.20]; Lnr2, npnx = (0.20,0.65]; Lnr3, npnx > 0.65. The GMD for pN-classification was 5.5 (standard error: ± 0.9) years, not much improved over a simple node-negative vs. node-positive that showed a GMD of 5.0 (± 1.4) years. The GMD for LNRc-classification was larger, 6.7 (± 0.8) years. Among other conventional metrics, Cox-model LNRc's c-index was 0.668 vs. pN's c = 0.641, indicating commensurate superiority of LNRc-classification. The usability of GMD-RMSTs warrants further investigation.
format Online
Article
Text
id pubmed-8863879
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-88638792022-02-23 Gini's mean difference and the long-term prognostic value of nodal quanta classes after pre-operative chemotherapy in advanced breast cancer Vinh-Hung, Vincent Van Parijs, Hilde Gorobets, Olena Fontaine, Christel Nguyen, Nam P. Keam, Bhumsuk Nguyen, Dung Minh De Ridder, Mark Sci Rep Article Gini's mean difference (GMD, mean absolute difference between any two distinct quantities) of the restricted mean survival times (RMSTs, expectation of life at a given time limit) has been proposed as a new metric where higher GMD indicates better prognostic value. GMD is applied to the RMSTs at 25 years time-horizon to evaluate the long-term overall survival of women with breast cancer who received neoadjuvant chemotherapy, comparing a classification based on the number (pN) versus a classification based on the ratio (LNRc) of positive nodes found at axillary surgery. A total of 233 patients treated in 1980–2009 with documented number of positive nodes (npos) and number of nodes examined (ntot) were identified. The numbers were categorized into pN0, npos = 0; pN1, npos = [1,3]; pN2, npos = [4,9]; pN3, npos ≥ 10. The ratios npnx = npos/ntot were categorized into Lnr0, npnx = 0; Lnr1, npnx = (0,0.20]; Lnr2, npnx = (0.20,0.65]; Lnr3, npnx > 0.65. The GMD for pN-classification was 5.5 (standard error: ± 0.9) years, not much improved over a simple node-negative vs. node-positive that showed a GMD of 5.0 (± 1.4) years. The GMD for LNRc-classification was larger, 6.7 (± 0.8) years. Among other conventional metrics, Cox-model LNRc's c-index was 0.668 vs. pN's c = 0.641, indicating commensurate superiority of LNRc-classification. The usability of GMD-RMSTs warrants further investigation. Nature Publishing Group UK 2022-02-22 /pmc/articles/PMC8863879/ /pubmed/35194143 http://dx.doi.org/10.1038/s41598-022-07078-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Vinh-Hung, Vincent
Van Parijs, Hilde
Gorobets, Olena
Fontaine, Christel
Nguyen, Nam P.
Keam, Bhumsuk
Nguyen, Dung Minh
De Ridder, Mark
Gini's mean difference and the long-term prognostic value of nodal quanta classes after pre-operative chemotherapy in advanced breast cancer
title Gini's mean difference and the long-term prognostic value of nodal quanta classes after pre-operative chemotherapy in advanced breast cancer
title_full Gini's mean difference and the long-term prognostic value of nodal quanta classes after pre-operative chemotherapy in advanced breast cancer
title_fullStr Gini's mean difference and the long-term prognostic value of nodal quanta classes after pre-operative chemotherapy in advanced breast cancer
title_full_unstemmed Gini's mean difference and the long-term prognostic value of nodal quanta classes after pre-operative chemotherapy in advanced breast cancer
title_short Gini's mean difference and the long-term prognostic value of nodal quanta classes after pre-operative chemotherapy in advanced breast cancer
title_sort gini's mean difference and the long-term prognostic value of nodal quanta classes after pre-operative chemotherapy in advanced breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863879/
https://www.ncbi.nlm.nih.gov/pubmed/35194143
http://dx.doi.org/10.1038/s41598-022-07078-7
work_keys_str_mv AT vinhhungvincent ginismeandifferenceandthelongtermprognosticvalueofnodalquantaclassesafterpreoperativechemotherapyinadvancedbreastcancer
AT vanparijshilde ginismeandifferenceandthelongtermprognosticvalueofnodalquantaclassesafterpreoperativechemotherapyinadvancedbreastcancer
AT gorobetsolena ginismeandifferenceandthelongtermprognosticvalueofnodalquantaclassesafterpreoperativechemotherapyinadvancedbreastcancer
AT fontainechristel ginismeandifferenceandthelongtermprognosticvalueofnodalquantaclassesafterpreoperativechemotherapyinadvancedbreastcancer
AT nguyennamp ginismeandifferenceandthelongtermprognosticvalueofnodalquantaclassesafterpreoperativechemotherapyinadvancedbreastcancer
AT keambhumsuk ginismeandifferenceandthelongtermprognosticvalueofnodalquantaclassesafterpreoperativechemotherapyinadvancedbreastcancer
AT nguyendungminh ginismeandifferenceandthelongtermprognosticvalueofnodalquantaclassesafterpreoperativechemotherapyinadvancedbreastcancer
AT deriddermark ginismeandifferenceandthelongtermprognosticvalueofnodalquantaclassesafterpreoperativechemotherapyinadvancedbreastcancer